EyePoint Pharmaceuticals, Inc. (EYPT)
Market: NASD |
Currency: USD
Address: 480 Pleasant Street
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Show more
📈 EyePoint Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$31.75
-
Upside/Downside from Analyst Target:
255.94%
-
Broker Call:
25
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
10-25%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2020 |
- |
$0.100000 |
- |
2020-12-09 |
- |
Stock split |
|
Total Amount for 2020: $0.100000 |
📅 Earnings & EPS History for EyePoint Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-05-05 (estimated upcoming) | - |
| 2026-03-03 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-05 (estimated upcoming) | - |
| 2025-08-04 (estimated upcoming) | - |
| 2025-05-07 | - |
| 2025-05-07 | -0.65 |
| 2025-05-06 | - |
| 2025-05-05 | - |
| 2025-03-05 | -0.64 |
| 2025-03-04 | - |
| 2024-10-28 | -0.54 |
| 2024-08-07 | -0.58 |
| 2024-08-06 | -0.58 |
| 2024-05-08 | -0.55 |
| 2024-05-07 | -0.55 |
| 2024-03-07 | -0.33 |
| 2024-03-06 | -0.33 |
| 2023-11-01 | -0.33 |
| 2023-10-31 | -0.33 |
| 2023-08-02 | -0.61 |
| 2023-08-01 | -0.61 |
| 2023-05-03 | -0.56 |
| 2023-05-02 | -0.56 |
| 2023-03-02 | -1.16 |
| 2023-03-01 | -1.16 |
| 2022-11-02 | -0.49 |
| 2022-11-01 | -0.49 |
| 2022-08-03 | -0.52 |
| 2022-08-02 | -0.52 |
| 2022-05-04 | -0.56 |
| 2022-05-03 | -0.56 |
| 2022-03-03 | -0.59 |
| 2022-03-02 | -0.59 |
| 2021-11-03 | -0.58 |
| 2021-11-02 | -0.58 |
| 2021-08-04 | -0.35 |
| 2021-08-03 | -0.35 |
| 2021-05-05 | -0.5 |
| 2021-05-04 | -0.5 |
| 2021-03-04 | -1 |
| 2021-03-03 | -1 |
| 2020-11-05 | -0.3 |
| 2020-11-04 | -0.3 |
| 2020-08-05 | -1 |
| 2020-08-04 | -1 |
| 2020-05-06 | -1.1 |
| 2020-05-05 | -1.1 |
| 2020-03-05 | -1 |
| 2020-03-04 | -1 |
| 2019-11-06 | -1.5 |
| 2019-08-06 | -1.1 |
| 2019-05-07 | -1.6 |
| 2019-03-13 | -1.2 |
| 2018-11-05 | -1.9 |
| 2018-09-11 | -1.9 |
| 2018-05-07 | -1.1 |
| 2018-02-06 | -0.13 |
| 2017-11-06 | -1.5 |
| 2017-09-10 | -1.6 |
| 2017-05-03 | -1.5 |
| 2017-02-06 | - |
| 2016-11-06 | -2.1 |
| 2016-09-11 | -1.9 |
| 2016-05-04 | -1.5 |
| 2016-02-07 | -1.8 |
| 2015-11-04 | -1.7 |
| 2015-09-08 | -1.7 |
| 2015-05-07 | -1.7 |
| 2015-02-04 | -1.4 |
| 2014-11-06 | 6.7 |
| 2014-09-08 | -1.4 |
| 2014-05-12 | -0.8 |
| 2014-02-06 | -1.3 |
| 2013-11-11 | -1.4 |
| 2013-09-24 | -1.7 |
| 2013-05-12 | -1.2 |
| 2013-02-05 | -1.1 |
| 2012-11-07 | -1.1 |
| 2012-09-23 | -1.1 |
| 2012-05-08 | -1.3 |
| 2012-02-07 | -1.3 |
| 2011-11-06 | -1.2 |
| 2011-09-11 | -0.1 |
| 2011-05-09 | -1.3 |
| 2011-02-08 | -1.5 |
| 2010-11-04 | -1.7 |
| 2010-05-11 | - |
📰 Related News & Research
No related articles found for "eyepoint pharmaceuticals".
